Migraine Briefs

Migraine: Triptan responders are more likely to respond to erenumab


 

Key clinical point: Patients with migraine who showed a favorable response to at least one triptan had a higher likelihood to respond to erenumab treatment than those not responding to triptans.

Major finding: Triptan responders had higher odds for responding to erenumab treatment than the triptan nonresponders (odds ratio, 3.64; P = .014).

Study details: Findings are from an ancillary study from a real-life observational study involving 140 patients with migraine treated with erenumab for at least 6 months.

Disclosures: The publication fee was unconditionally granted by Novartis Farma S.r.l. The lead author along with some other authors declared no competing interests. Some authors declared financial and nonfinancial relationships with various pharmaceutical sources such as Eli Lilly, Novartis, Allergan, Teva, Abbott, Innovet Italia Srl, Epitech Group, and Lusofarmaco.

Source:Frattale I et al. J Headache Pain. 2021 Jan 6. doi: 10.1186/s10194-020-01213-3.

Recommended Reading

Fremanezumab may be effective in reversion of chronic to episodic migraine
Migraine ICYMI
Is ginger effective for migraine?
Migraine ICYMI
Pediatric mild traumatic brain injury: Comorbidities of emotional distress and migraine linked to longer recoveries
Migraine ICYMI
Interictal plasma amylin as a diagnostic biomarker for chronic migraine
Migraine ICYMI
Idiopathic intracranial hypertension is on the rise
Migraine ICYMI
Reversion from chronic to episodic migraine with erenumab
Migraine ICYMI
Real-world effectiveness of erenumab in migraine
Migraine ICYMI
PFO closure reduces migraine: New meta-analysis
Migraine ICYMI
Researchers examine factors associated with opioid use among migraineurs
Migraine ICYMI
The true measure of cluster headache
Migraine ICYMI